Form 10-Q REXAHN PHARMACEUTICALS, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Rexahn (RNN) Valuation Remains Compelling at Supinoxin, RX-3117 Phase 1 Milestones Near - Roth Capital
May 11, 2015 3:10 PM EDTRoth Capital reaffirms its Buy rating and $3 price target on Rexahn Pharmaceuticals (NYSE: RNN) following Q1 results issued earlier. Rexahn posted Q1 loss of $0.02 per share, versus the consensus loss estimate of $0.03 per share.
Analyst Joseph Pantginis commented, RNN is nearing two clinical milestones with the anticipated data releases from the two dose-escalation... More
Rexahn Pharma (RNN) Tops Q1 EPS by 1c
May 11, 2015 9:06 AM EDTRexahn Pharma (NYSE: RNN) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).
For earnings history and earnings-related data on Rexahn Pharma (RNN) click here.
... More